JIP
PACB icon

Jaffetilchin Investment Partners’s Pacific Biosciences PACB Stock Holding History

Jaffetilchin Investment Partners’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$170 – 1007
2024
Q3 		$170 Buy
+100
New +$164 ﹤0.01% 1325

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jaffetilchin Investment Partners's PACB Position: Q4 2024 in Review

Jaffetilchin Investment Partners sold out of Pacific Biosciences (PACB) in Q4 2024, closing a stake of 100 shares — an estimated $170 sold.

Jaffetilchin Investment Partners first reported a position in PACB in Q3 2024 and held it in 1 quarter. The position peaked at $170 in Q3 2024. 226 funds tracked by Wall St. Rank hold PACB as of Q4 2024.

  • Jaffetilchin Investment Partners reported no remaining Pacific Biosciences position as of Q4 2024 after selling out during the quarter.
  • Jaffetilchin Investment Partners sold 100 Pacific Biosciences shares in Q4 2024, an estimated $170.
  • Jaffetilchin Investment Partners first reported a position in Pacific Biosciences in Q3 2024 and held it in 1 quarter.
  • Jaffetilchin Investment Partners's Pacific Biosciences position peaked at $170 in Q3 2024.
  • 226 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2024.

Based on Jaffetilchin Investment Partners's 13F filing for Q4 2024, filed 13 Feb 2025.